Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Astellas
Pharma
Astellas, Takeda, RA Capital—Fierce Pharma Asia
Astellas CEO lays out the firm's new five-year plan. Takeda beats BMS in a psoriasis trial. RA provides China capabilities to its portfolio. And more.
Angus Liu
Jun 12, 2026 8:23am
Inside Astellas CEO's plan to counter Xtandi's patent cliff
Jun 11, 2026 6:00pm
More biotech hawkishness, Pfizer’s $10B deal—Fierce Pharma Asia
May 29, 2026 8:30am
Led by Lilly, 8 companies reach double-digit revenue gains in Q1
May 21, 2026 9:00am
Sun-Organon, Astellas, BeOne—Fierce Pharma Asia
May 1, 2026 8:43am
Astellas projects Xtandi decline but overall growth in FY2026
Apr 27, 2026 11:30am
